Compare GSK plc (GSK) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Texas Instruments Incorporated — how do they compare? GSK plc trades at $52.8 (market cap $101.34B), while Texas Instruments Incorporated trades at $289.88 (market cap $274.11B). The key difference: Texas Instruments Incorporated is far larger — about 2.7× GSK plc's market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | TXN | |
|---|---|---|
Market Cap | $101.34B | $274.11B |
Sector | Health | Technology |
52-Week High | $61.18 | $332.35 |
52-Week Low | $36.20 | $153.33 |
Enterprise Value | $121.95B | $283.06B |
Dividend Yield | 3.49% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Texas Instruments (TXN) trades at $305.55, up 2.34% with a bullish technical signal. Recent Q1 2026 earnings beat expectations, with revenue growth to $17.68 billion in 2025. The company maintains strong profitability with 29.11% net margin and announced a CFO transition with Julie Knecht succeeding Rafael Lizardi in August 2026. Analysts show a buy consensus with a $317.20 price target, though valuation ratios like P/E of 52.23 appear elevated.
Outlook remains positive driven by AI data center demand and 300mm capacity expansion, but risks include high debt-to-asset ratio of 40.61% and competitive pressures. The stock presents growth potential with disciplined risk management advised given premium valuation and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
